This Computer-Aided Drug Discovery market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The computer aided drug discovery market size has grown rapidly in recent years. It will grow from $5.94 billion in 2023 to $6.69 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth during the historic period can be attributed to advancements in computational power, improvements in molecular modeling, rising demand from the pharmaceutical industry, support from regulatory bodies, and increased collaborations.
The computer aided drug discovery market size is expected to see rapid growth in the next few years. It will grow to $10.83 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The growth projected for the forecast period can be attributed to the integration of AI and machine learning into drug discovery processes, a shift toward personalized medicine, increased availability of big data, the development and adoption of cloud-based platforms for CADD, and the creation of novel therapeutics. Major trends during this period include a growing emphasis on collaboration among various stakeholders, the expansion of AI-driven platforms providing end-to-end solutions for drug discovery, and ongoing product innovations.
The increasing prevalence of cancer cases is projected to drive the growth of the computer-aided drug discovery market in the coming years. Cancer encompasses a range of diseases marked by the uncontrolled growth and division of abnormal cells within the body. The rising number of cancer cases can be attributed to various factors, including lifestyle changes, urbanization, environmental pollution, and the consumption of tobacco and alcohol, as well as disparities in healthcare access and awareness. Computer-aided drug discovery can facilitate the design of drugs that target cancer cells with specific genetic mutations, leading to more personalized and effective cancer treatments. For instance, in May 2024, the National Cancer Institute, a US-based agency focused on cancer research and training, reported nearly 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. These figures are expected to rise significantly by 2040, with projections of approximately 29.9 million new cases and 15.3 million deaths each year. Consequently, the growing prevalence of cancer cases is driving the expansion of the computer-aided drug discovery market.
Leading companies in the computer-aided drug discovery (CADD) market are advancing innovative solutions, such as incorporating artificial intelligence (AI) into drug discovery, to improve the accuracy, speed, and efficiency of identifying potential drug candidates, optimizing lead compounds, and supporting the development of personalized medicine. AI in drug discovery involves the use of technologies like machine learning and deep learning, which rely on advanced algorithms to accelerate and enhance the precision of discovering and developing new drugs. For example, in December 2023, Merck KGaA, a science and technology company based in Germany, launched AIDDISONTM, a software-as-a-service platform that integrates drug discovery and synthesis. AIDDISONTM combines generative AI, machine learning, and computer-aided drug design to speed up drug development by virtually screening compounds from over 60 billion chemical targets and recommending the best synthesis routes. The platform is built on two decades of pharmaceutical R&D data to identify drug-like candidates with properties such as non-toxicity and stability. By integrating Merck's SynthiaTM retrosynthesis API, AIDDISONTM also optimizes drug manufacturing for greater efficiency and sustainability, with the goal of reducing the time and cost of drug discovery.
In January 2022, Schrödinger Inc., a US-based company specializing in computational tools and software for drug discovery, acquired XTAL BioStructures Inc. for $6 million. This acquisition supports Schrödinger's strategy to advance structure-based drug discovery by integrating its computational platform with experimental structural biology methods. XTAL BioStructures, a US-based biotechnology company, provides structural biology services and reagents to support drug discovery programs.
Major companies operating in the computer-aided drug discovery market are Dassault Systèmes SE, PerkinElmer Inc., Roivant Sciences Ltd., Certara Inc., Schrödinger Inc., XtalPi Inc., Dotmatics Limited, Simulations Plus Inc., ChemAxon Ltd., Exscientia Ltd., Insilico Medicine Inc., Collaborative Drug Discovery Inc., OpenEye Scientific Software Inc., Nimbus Therapeutics LLC, Atomwise Inc., GNS Healthcare Inc., BenevolentAI Limited, EpiVax Inc., Numerate Inc., Cloud Pharmaceuticals Inc., Aris Pharmaceuticals Inc., Cyclica Inc., BioSolveIT GmbH, Chemical Computing Group ULC, InSilicoTrials Technologies S.p.A.
North America was the largest region in the computer-aided drug discovery (CADD) market in 2023. The regions covered in the computer-aided drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the computer-aided drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Computer-aided drug discovery (CADD) is a methodology that uses computational techniques and algorithms to speed up the drug discovery process. It involves leveraging computer software and advanced technologies to identify, design, and optimize potential drug candidates targeting specific biological sites.
The main types of computer-aided drug discovery include structure-based drug design, ligand-based drug design, and sequence-based approaches. Structure-based drug design (SBDD) focuses on designing molecules based on the 3D structure of a biological target, usually a protein, which is obtained through methods such as X-ray crystallography or NMR spectroscopy. These techniques are applied in various therapeutic areas such as oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and more, and are utilized by pharmaceutical companies, biotechnology firms, and research laboratories.
The computer-aided drug discovery market research report is one of a series of new reports that provides computer-aided drug discovery market statistics, including computer-aided drug discovery industry global market size, regional shares, competitors with a computer-aided drug discovery market share, detailed computer-aided drug discovery market segments, market trends, and opportunities, and any further data you may need to thrive in the computer-aided drug discovery industry. This computer aided drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The computer-aided drug discovery market consists of revenues earned by entities by providing molecular modeling, virtual screening, and pharmacophore modeling. The computer-aided drug discovery(CADD) market also includes sales of multi-target drug design and 3D-QSAR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The computer aided drug discovery market size has grown rapidly in recent years. It will grow from $5.94 billion in 2023 to $6.69 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth during the historic period can be attributed to advancements in computational power, improvements in molecular modeling, rising demand from the pharmaceutical industry, support from regulatory bodies, and increased collaborations.
The computer aided drug discovery market size is expected to see rapid growth in the next few years. It will grow to $10.83 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The growth projected for the forecast period can be attributed to the integration of AI and machine learning into drug discovery processes, a shift toward personalized medicine, increased availability of big data, the development and adoption of cloud-based platforms for CADD, and the creation of novel therapeutics. Major trends during this period include a growing emphasis on collaboration among various stakeholders, the expansion of AI-driven platforms providing end-to-end solutions for drug discovery, and ongoing product innovations.
The increasing prevalence of cancer cases is projected to drive the growth of the computer-aided drug discovery market in the coming years. Cancer encompasses a range of diseases marked by the uncontrolled growth and division of abnormal cells within the body. The rising number of cancer cases can be attributed to various factors, including lifestyle changes, urbanization, environmental pollution, and the consumption of tobacco and alcohol, as well as disparities in healthcare access and awareness. Computer-aided drug discovery can facilitate the design of drugs that target cancer cells with specific genetic mutations, leading to more personalized and effective cancer treatments. For instance, in May 2024, the National Cancer Institute, a US-based agency focused on cancer research and training, reported nearly 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. These figures are expected to rise significantly by 2040, with projections of approximately 29.9 million new cases and 15.3 million deaths each year. Consequently, the growing prevalence of cancer cases is driving the expansion of the computer-aided drug discovery market.
Leading companies in the computer-aided drug discovery (CADD) market are advancing innovative solutions, such as incorporating artificial intelligence (AI) into drug discovery, to improve the accuracy, speed, and efficiency of identifying potential drug candidates, optimizing lead compounds, and supporting the development of personalized medicine. AI in drug discovery involves the use of technologies like machine learning and deep learning, which rely on advanced algorithms to accelerate and enhance the precision of discovering and developing new drugs. For example, in December 2023, Merck KGaA, a science and technology company based in Germany, launched AIDDISONTM, a software-as-a-service platform that integrates drug discovery and synthesis. AIDDISONTM combines generative AI, machine learning, and computer-aided drug design to speed up drug development by virtually screening compounds from over 60 billion chemical targets and recommending the best synthesis routes. The platform is built on two decades of pharmaceutical R&D data to identify drug-like candidates with properties such as non-toxicity and stability. By integrating Merck's SynthiaTM retrosynthesis API, AIDDISONTM also optimizes drug manufacturing for greater efficiency and sustainability, with the goal of reducing the time and cost of drug discovery.
In January 2022, Schrödinger Inc., a US-based company specializing in computational tools and software for drug discovery, acquired XTAL BioStructures Inc. for $6 million. This acquisition supports Schrödinger's strategy to advance structure-based drug discovery by integrating its computational platform with experimental structural biology methods. XTAL BioStructures, a US-based biotechnology company, provides structural biology services and reagents to support drug discovery programs.
Major companies operating in the computer-aided drug discovery market are Dassault Systèmes SE, PerkinElmer Inc., Roivant Sciences Ltd., Certara Inc., Schrödinger Inc., XtalPi Inc., Dotmatics Limited, Simulations Plus Inc., ChemAxon Ltd., Exscientia Ltd., Insilico Medicine Inc., Collaborative Drug Discovery Inc., OpenEye Scientific Software Inc., Nimbus Therapeutics LLC, Atomwise Inc., GNS Healthcare Inc., BenevolentAI Limited, EpiVax Inc., Numerate Inc., Cloud Pharmaceuticals Inc., Aris Pharmaceuticals Inc., Cyclica Inc., BioSolveIT GmbH, Chemical Computing Group ULC, InSilicoTrials Technologies S.p.A.
North America was the largest region in the computer-aided drug discovery (CADD) market in 2023. The regions covered in the computer-aided drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the computer-aided drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Computer-aided drug discovery (CADD) is a methodology that uses computational techniques and algorithms to speed up the drug discovery process. It involves leveraging computer software and advanced technologies to identify, design, and optimize potential drug candidates targeting specific biological sites.
The main types of computer-aided drug discovery include structure-based drug design, ligand-based drug design, and sequence-based approaches. Structure-based drug design (SBDD) focuses on designing molecules based on the 3D structure of a biological target, usually a protein, which is obtained through methods such as X-ray crystallography or NMR spectroscopy. These techniques are applied in various therapeutic areas such as oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and more, and are utilized by pharmaceutical companies, biotechnology firms, and research laboratories.
The computer-aided drug discovery market research report is one of a series of new reports that provides computer-aided drug discovery market statistics, including computer-aided drug discovery industry global market size, regional shares, competitors with a computer-aided drug discovery market share, detailed computer-aided drug discovery market segments, market trends, and opportunities, and any further data you may need to thrive in the computer-aided drug discovery industry. This computer aided drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The computer-aided drug discovery market consists of revenues earned by entities by providing molecular modeling, virtual screening, and pharmacophore modeling. The computer-aided drug discovery(CADD) market also includes sales of multi-target drug design and 3D-QSAR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Computer-Aided Drug Discovery Market Characteristics3. Computer-Aided Drug Discovery Market Trends and Strategies32. Global Computer-Aided Drug Discovery Market Competitive Benchmarking33. Global Computer-Aided Drug Discovery Market Competitive Dashboard34. Key Mergers and Acquisitions in the Computer-Aided Drug Discovery Market
4. Computer-Aided Drug Discovery Market - Macro Economic Scenario
5. Global Computer-Aided Drug Discovery Market Size and Growth
6. Computer-Aided Drug Discovery Market Segmentation
7. Computer-Aided Drug Discovery Market Regional and Country Analysis
8. Asia-Pacific Computer-Aided Drug Discovery Market
9. China Computer-Aided Drug Discovery Market
10. India Computer-Aided Drug Discovery Market
11. Japan Computer-Aided Drug Discovery Market
12. Australia Computer-Aided Drug Discovery Market
13. Indonesia Computer-Aided Drug Discovery Market
14. South Korea Computer-Aided Drug Discovery Market
15. Western Europe Computer-Aided Drug Discovery Market
16. UK Computer-Aided Drug Discovery Market
17. Germany Computer-Aided Drug Discovery Market
18. France Computer-Aided Drug Discovery Market
19. Italy Computer-Aided Drug Discovery Market
20. Spain Computer-Aided Drug Discovery Market
21. Eastern Europe Computer-Aided Drug Discovery Market
22. Russia Computer-Aided Drug Discovery Market
23. North America Computer-Aided Drug Discovery Market
24. USA Computer-Aided Drug Discovery Market
25. Canada Computer-Aided Drug Discovery Market
26. South America Computer-Aided Drug Discovery Market
27. Brazil Computer-Aided Drug Discovery Market
28. Middle East Computer-Aided Drug Discovery Market
29. Africa Computer-Aided Drug Discovery Market
30. Computer-Aided Drug Discovery Market Competitive Landscape and Company Profiles
31. Computer-Aided Drug Discovery Market Other Major and Innovative Companies
35. Computer-Aided Drug Discovery Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Computer-Aided Drug Discovery Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on computer-aided drug discovery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for computer-aided drug discovery? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The computer-aided drug discovery market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Structure Based Drug Design; Ligand-Based Drug Design; Sequence-Based Approaches2) By Therapeutic Area: Oncology; Neurology; Cardiovascular Disease; Respiratory Disease; Diabetes; Other Therapeutic Areas
3) By End User: Pharmaceutical Companies; Biotechnology Companies; Research Laboratories
Key Companies Mentioned: Dassault Systèmes SE; PerkinElmer Inc.; Roivant Sciences Ltd.; Certara Inc.; Schrödinger Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies profiled in this Computer-Aided Drug Discovery market report include:- Dassault Systèmes SE
- PerkinElmer Inc.
- Roivant Sciences Ltd.
- Certara Inc.
- Schrödinger Inc.
- XtalPi Inc.
- Dotmatics Limited
- Simulations Plus Inc.
- ChemAxon Ltd.
- Exscientia Ltd.
- Insilico Medicine Inc.
- Collaborative Drug Discovery Inc.
- OpenEye Scientific Software Inc.
- Nimbus Therapeutics LLC
- Atomwise Inc.
- GNS Healthcare Inc.
- BenevolentAI Limited
- EpiVax Inc.
- Numerate Inc.
- Cloud Pharmaceuticals Inc.
- Aris Pharmaceuticals Inc.
- Cyclica Inc.
- BioSolveIT GmbH
- Chemical Computing Group ULC
- InSilicoTrials Technologies S.p.A
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | December 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 6.69 Billion |
| Forecasted Market Value ( USD | $ 10.83 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
